Emergent BioSolutions (EBS) Equity Average (2011 - 2026)

Emergent BioSolutions' Equity Average history runs 16 years deep, the most recent figure standing at $522.8 million for Q1 2026.

• In Q1 2026, Equity Average rose 0.99% year-over-year to $522.8 million; the TTM figure through Mar 2026 stood at $522.8 million (up 0.99% YoY), while the FY2025 annual figure was $502.7 million, down 11.19% from the prior year.
• Equity Average was $522.8 million for Q1 2026 at Emergent BioSolutions, down from $552.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.6 billion in Q1 2022 to a low of $447.4 million in Q3 2024.
• Historically, Equity Average has averaged $865.1 million across 5 years, with a median of $656.6 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Equity Average sank 52.26% in 2023, then gained 25.04% in 2025.
• A 5-year view of Equity Average shows it stood at $1.4 billion in 2022, then tumbled by 52.26% to $673.2 million in 2023, then decreased by 26.39% to $495.6 million in 2024, then gained by 11.49% to $552.6 million in 2025, then dropped by 5.38% to $522.8 million in 2026.
• The last three Equity Average figures came in at $522.8 million (Q1 2026), $552.6 million (Q4 2025), and $559.4 million (Q3 2025), per Business Quant data.